EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Protein degraders - from thalidomide to new PROTACs

Takumi Ito iD

The Journal of Biochemistry · 2024

DOI: 10.1093/jb/mvad113 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Biochemistry, 2024. Verfasst von Takumi Ito. Beteiligte Einrichtung: Institute of Medical Science, Tokyo Medical University, 6-1-1, Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan. Hauptthemen laut MEDLINE: Thalidomide, Proteolysis, Ubiquitin-Protein Ligases. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 137 Literaturangaben. Gefördert von: Japan Society for the Promotion of Science and the Ministry of Education, Culture, Sports, Science and Technology (JSPS/MEXT KAKENHI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recently, the development of protein degraders (protein-degrading compounds) has prominently progressed. There are two remarkable classes of protein degraders: proteolysis-targeting chimeras (PROTACs) and molecular glue degraders (MGDs). Almost 70 years have passed since thalidomide was initially developed as a sedative-hypnotic drug, which is currently recognized as one of the most well-known MGDs. During the last two decades, a myriad of PROTACs and MGDs have been developed, and the molecular mechanism of action (MOA) of thalidomide was basically elucidated, including identifying its molecular target cereblon (CRBN). CRBN forms a Cullin Ring Ligase 4 with Cul4 and DDB1, whose substrate specificity is controlled by its binding ligands. Thalidomide, lenalidomide and pomalidomide, three CRBN-binding MGDs, were clinically approved to treat several intractable diseases (including multiple myeloma). Several other MGDs and CRBN-based PROTACs (ARV-110 and AVR-471) are undergoing clinical trials. In addition, several new related technologies regarding PROTACs and MGDs have also been developed, and achievements of protein degraders impact not only therapeutic fields but also basic biological science. In this article, I introduce the history of protein degraders, from the development of thalidomide to the latest PROTACs and related technologies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThalidomideProteolysisUbiquitin-Protein LigasesHumansAdaptor Proteins, Signal TransducingMultiple MyelomaProteolysis Targeting Chimera

Stichwörter der Autor:innen

PROTACscereblonmolecular glue degraderprotein degraderthalidomideubiquitin

Substanzen

ThalidomideUbiquitin-Protein LigasesCRBN protein, humanAdaptor Proteins, Signal TransducingpomalidomideProteolysis Targeting Chimera

Autor:innen und Institutionen

  • Institute of Medical Science, Tokyo Medical University, 6-1-1, Shinjuku, Shinjuku-ku, Tokyo 160-8402, Japan.

ORCID-Profile: Takumi Ito

Förderung

  • Japan Society for the Promotion of Science and the Ministry of Education, Culture, Sports, Science and Technology (JSPS/MEXT KAKENHI)

Zitieren

APA

Ito, T. (2024). Protein degraders - from thalidomide to new PROTACs. The Journal of Biochemistry. https://doi.org/10.1093/jb/mvad113

Vancouver

Ito T. Protein degraders - from thalidomide to new PROTACs. The Journal of Biochemistry. 2024. doi:10.1093/jb/mvad113

BibTeX
@article{Ito2024,
  author = {Ito, Takumi},
  title = {Protein degraders - from thalidomide to new PROTACs},
  journal = {The Journal of Biochemistry},
  year = {2024},
  doi = {10.1093/jb/mvad113}
}
Kostenlos starten →